Kenneth Kam-Wing Lo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kenneth Kam-Wing Lo has a total of 382 co-authors. Here are the top co-authors by number of shared publications:
- Lawrence Cho-Cheung Lee
Department of Chemistry, City University of Hong Kong, Tat Chee Avenue, Kowloon, Hong Kong, P. R. China
34 shared publications Kenneth Yin Zhang
Key Laboratory for Organic Electronics and Information Displays and Jiangsu Key Laboratory for Biosensors, Institute of Advanced Materials (IAM), Jiangsu National Synergetic Innovation Center for Advanced Materials (SICAM) , Nanjing University of Posts & Telecommunications , 9 Wenyuan Road , Nanjing 210023 , P. R. China
27 shared publicationsHua-Wei Liu
Department of Chemistry, City University of Hong Kong, Tat Chee Avenue, Kowloon, Hong Kong, P. R. China
24 shared publications- Peter Kam-Keung Leung
Department of Chemistry, City University of Hong Kong, Tat Chee Avenue, Kowloon, Hong Kong, P. R. China
21 shared publications Vivian Wing-Wah Yam
17 shared publications- Nianyong Zhu
Hong Kong Baptist University
16 shared publications
Latest Publications
- Open Access
- 21 October 2026
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 17 (40) , 19469-19482
Exploring chemical space for iridium( iii ) complexes: a direct-to-biology (D2B) approach to identifying anticancer and antibacterial agents
A direct-to-biology approach was used to screen 336 Ir 3+ complexes against bacteria and cancer cells. High throughput experiments and ML models revealed divergent antibacterial and anticancer chemical space.
- 21 October 2026
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 17 (40) , 19469-19482
Open AccessExploring chemical space for iridium( iii ) complexes: a direct-to-biology (D2B) approach to identifying anticancer and antibacterial agents
A direct-to-biology approach was used to screen 336 Ir 3+ complexes against bacteria and cancer cells. High throughput experiments and ML models revealed divergent antibacterial and anticancer chemical space.
- Open Access
- 30 June 2026
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 148 (27) , 28238-28253
Enzyme-Responsive Chemiluminescent Probes Assembled with Iridium(III) Photosensitizers via Host–Guest Chemistry for Chemiluminescence-Induced Photodynamic Therapy
Photodynamic therapy (PDT) is effective for localized cancers, but its reliance on external light limits treatment depth and uniformity. Herein, we report a programmable supramolecular chemiluminescence (CL)-induced PDT platform that generates reactive oxygen species (ROS) in the absence of light irradiation and displays intrinsic cancer selectivity. This platform is constructed through the supramolecular interaction between enzyme-responsive chemiluminescent spiroadamantyl phenoxy-1,2-dioxetane probes (ADOP, ADOE, and ADOG) and luminescent iridium(III) complexes bearing a trimethyl-β-cyclodextrin (TMCD) host [Ir(N∧C)2(bpy-TMCD)](Cl) (HN∧C = 2-phenylpyridine (Hppy) (1a), 2-phenylquinoline (Hpq) (2a), and 2-(1-naphthyl)benzothiazole (Hbsn) (3a)). The chemiluminescent probes exhibited CL upon reaction with alkaline phosphatase (ALP), porcine liver esterase (PLE), and β-galactosidase (β-gal); while the iridium(III) complexes showed intense phosphorescence with efficient singlet oxygen production, distinct intracellular localization, and tunable (photo)cytotoxicity. In aqueous solutions, mixing the chemiluminescent probes with TMCD-tagged iridium(III) complexes afforded supramolecular adducts that, upon enzyme activation, underwent chemiluminescence resonance energy transfer (CRET) from the dioxetane donors to the iridium(III) acceptors. Remarkably, the ALP-responsive conjugate formed from probe ADOP and complex 3a (adduct ADOP–3a) selectively generated ROS and elicited potent cytotoxicity in cancerous HeLa cells and spheroids under light-free conditions, with apoptosis as the predominant cell death pathway, while remaining noncytotoxic in normal HEK293 cells. This modular platform couples supramolecular host–guest assembly, enzyme-specific activation, and CRET-induced ROS generation to overcome the limitations of conventional PDT, enabling cancer-selective, light-free therapy.
- 30 June 2026
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 148 (27) , 28238-28253
Open AccessEnzyme-Responsive Chemiluminescent Probes Assembled with Iridium(III) Photosensitizers via Host–Guest Chemistry for Chemiluminescence-Induced Photodynamic Therapy
Photodynamic therapy (PDT) is effective for localized cancers, but its reliance on external light limits treatment depth and uniformity. Herein, we report a programmable supramolecular chemiluminescence (CL)-induced PDT platform that generates reactive oxygen species (ROS) in the absence of light irradiation and displays intrinsic cancer selectivity. This platform is constructed through the supramolecular interaction between enzyme-responsive chemiluminescent spiroadamantyl phenoxy-1,2-dioxetane probes (ADOP, ADOE, and ADOG) and luminescent iridium(III) complexes bearing a trimethyl-β-cyclodextrin (TMCD) host [Ir(N∧C)2(bpy-TMCD)](Cl) (HN∧C = 2-phenylpyridine (Hppy) (1a), 2-phenylquinoline (Hpq) (2a), and 2-(1-naphthyl)benzothiazole (Hbsn) (3a)). The chemiluminescent probes exhibited CL upon reaction with alkaline phosphatase (ALP), porcine liver esterase (PLE), and β-galactosidase (β-gal); while the iridium(III) complexes showed intense phosphorescence with efficient singlet oxygen production, distinct intracellular localization, and tunable (photo)cytotoxicity. In aqueous solutions, mixing the chemiluminescent probes with TMCD-tagged iridium(III) complexes afforded supramolecular adducts that, upon enzyme activation, underwent chemiluminescence resonance energy transfer (CRET) from the dioxetane donors to the iridium(III) acceptors. Remarkably, the ALP-responsive conjugate formed from probe ADOP and complex 3a (adduct ADOP–3a) selectively generated ROS and elicited potent cytotoxicity in cancerous HeLa cells and spheroids under light-free conditions, with apoptosis as the predominant cell death pathway, while remaining noncytotoxic in normal HEK293 cells. This modular platform couples supramolecular host–guest assembly, enzyme-specific activation, and CRET-induced ROS generation to overcome the limitations of conventional PDT, enabling cancer-selective, light-free therapy.
- Open Access
- 18 June 2026
- Published by Springer Nature in Revista Brasileira de Farmacognosia
- Vol. 36 (1)
A Comparative Study of Marine Saponins from Sea Cucumbers as Potent Cytotoxic Agents Against Aggressive Human Cancer Cell Lines
- 18 June 2026
- Published by Springer Nature in Revista Brasileira de Farmacognosia
- Vol. 36 (1)
Open AccessA Comparative Study of Marine Saponins from Sea Cucumbers as Potent Cytotoxic Agents Against Aggressive Human Cancer Cell Lines
- Open Access
- 5 March 2026
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 17 (16) , 8197-8207
Mitochondria-targeting cyclometallated rhodium( iii ) complexes appended with two rhodamine units as Type I photosensitisers for bioimaging and photocytotoxicity applications by inducing pyroptosis
Cyclometallated rhodium( iii ) dirhodamine complexes targeted mitochondria and, upon photoirradiation, generated reactive oxygen species mainly via the Type I pathway, inducing gasdermin D-mediated pyroptosis through mitochondrial dysfunction.
- 5 March 2026
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 17 (16) , 8197-8207
Open AccessMitochondria-targeting cyclometallated rhodium( iii ) complexes appended with two rhodamine units as Type I photosensitisers for bioimaging and photocytotoxicity applications by inducing pyroptosis
Cyclometallated rhodium( iii ) dirhodamine complexes targeted mitochondria and, upon photoirradiation, generated reactive oxygen species mainly via the Type I pathway, inducing gasdermin D-mediated pyroptosis through mitochondrial dysfunction.
- Open Access
- 7 January 2026
- Published by Wiley in ChemistryEurope
- Vol. 4 (1)
Revisiting Cu(I)‐Dppm Chemistry: Bright Thermally Activated Delayed Fluorescence Luminescence, Anion Dependance, Mechanochromism, and Singlet Oxygen Generation of a Dinuclear Cu(I) Homoleptic Complex
The one‐step syntheses of highly luminescent Cu(I) dimetallic complexes are reported using Cu(I) salts and the commercially available dppm ligand. Three crystalline phases A – C , obtained either with PF 6 − ( A and B : [Cu 2 (μ 2 ‐dppm) 3 ](PF 6 ) 2 ) or TEF − ( C : [Cu 2 (μ 2 ‐dppm) 3 ](TEF) 2 ) anions, display distinct conformations and crystal packings that strongly influence photophysical properties. All phases show intense solid‐state thermally activated delayed fluorescence with room temperature quantum yields of nearly 100%. Emission energies and decay times are modulated by packing effects. Phases A and B exhibit pronounced mechanochromic luminescence upon gentle grinding, while phase C is mechanically insensitive, presumably due to its bulky and flexible counter‐anions. Density functional calculation/time‐dependent density functional calculations suggest that crystal packing impacts the structural molecular relaxation, in agreement with mechanochromic behaviors. In aerated CH 2 Cl 2 , these complexes generate singlet oxygen with quantum yield of up to 30%, highlighting their potential as photosensitizers.
- 7 January 2026
- Published by Wiley in ChemistryEurope
- Vol. 4 (1)
Open AccessRevisiting Cu(I)‐Dppm Chemistry: Bright Thermally Activated Delayed Fluorescence Luminescence, Anion Dependance, Mechanochromism, and Singlet Oxygen Generation of a Dinuclear Cu(I) Homoleptic Complex
The one‐step syntheses of highly luminescent Cu(I) dimetallic complexes are reported using Cu(I) salts and the commercially available dppm ligand. Three crystalline phases A – C , obtained either with PF 6 − ( A and B : [Cu 2 (μ 2 ‐dppm) 3 ](PF 6 ) 2 ) or TEF − ( C : [Cu 2 (μ 2 ‐dppm) 3 ](TEF) 2 ) anions, display distinct conformations and crystal packings that strongly influence photophysical properties. All phases show intense solid‐state thermally activated delayed fluorescence with room temperature quantum yields of nearly 100%. Emission energies and decay times are modulated by packing effects. Phases A and B exhibit pronounced mechanochromic luminescence upon gentle grinding, while phase C is mechanically insensitive, presumably due to its bulky and flexible counter‐anions. Density functional calculation/time‐dependent density functional calculations suggest that crystal packing impacts the structural molecular relaxation, in agreement with mechanochromic behaviors. In aerated CH 2 Cl 2 , these complexes generate singlet oxygen with quantum yield of up to 30%, highlighting their potential as photosensitizers.
- 4 December 2025
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 61 (98) , 19461-19464
A matrix metalloproteinase-responsive iridium( iii )-based hydrogel for cancer cell-specific imaging and lysosome-targeted photodynamic therapy
A matrix metalloproteinase-sensitive iridium( iii )-based hydrogel selectively delivered lysosome-targeting iridium( iii ) complexes to cancer cells in response to elevated enzyme activity, offering a promising strategy for cancer imaging and therapy.
- 4 December 2025
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 61 (98) , 19461-19464
A matrix metalloproteinase-responsive iridium( iii )-based hydrogel for cancer cell-specific imaging and lysosome-targeted photodynamic therapy
A matrix metalloproteinase-sensitive iridium( iii )-based hydrogel selectively delivered lysosome-targeting iridium( iii ) complexes to cancer cells in response to elevated enzyme activity, offering a promising strategy for cancer imaging and therapy.
- Open Access
- 17 November 2025
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 16 (47) , 22266-22290
Ultrasound-activatable transition metal complexes to potentiate sonodynamic therapy
We summarise recent advances in transition metal complexes as sonosensitisers for sonodynamic therapy (SDT) in treating cancer, microbial infections and cardiovascular diseases, aiming to advance the clinical use of SDT and improve patient outcomes.
- 17 November 2025
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 16 (47) , 22266-22290
Open AccessUltrasound-activatable transition metal complexes to potentiate sonodynamic therapy
We summarise recent advances in transition metal complexes as sonosensitisers for sonodynamic therapy (SDT) in treating cancer, microbial infections and cardiovascular diseases, aiming to advance the clinical use of SDT and improve patient outcomes.
- Open Access
- 21 October 2025
- Published by Wiley in Angewandte Chemie
- Vol. 137 (50)
Controlled Dual Activation of Rhenium(I) Photosensitizers and Profluorophores/Prodrugs via a Dissociative Bioorthogonal Tetrazine–Isonitrile Reaction
Strategies for prodrug activation have been developed to enhance treatment efficacy, with bioorthogonal dissociation reactions emerging as a promising approach due to their remarkable specificity. In this work, we designed three rhenium(I) polypyridine complexes featuring a tetrazylmethyl (TzMe) group capable of bioorthogonal activation by 3‐isocyanopropyl (ICPr) or 3‐isocyanopropyl‐1‐carbamoyl (ICPrc) derivatives. This design serves as a dual‐release platform, which liberates rhenium(I) 3‐hydroxypyridine complexes and functional payloads from rhenium(I) TzMe complexes and ICPr/ICPrc‐caged compounds, respectively. Upon incubation with an ICPrc derivative, the TzMe complexes exhibited strong emission in acidic buffers, attributed to the predominant existence of the resulting rhenium(I) 3‐hydroxypyridine complexes in their protonated form. Confocal imaging of live cells incubated with a TzMe complex and ICPr‐caged fluorescein unveiled intense intracellular emission in distinct channels. Importantly, the therapeutic potential of this approach was underscored by the treatment of cells with a TzMe complex and ICPrc‐caged doxorubicin. The anticancer effect was amplified through the synergy between singlet oxygen ( 1 O 2 ) photosensitization and prodrug activation, effectively combining photodynamic therapy with chemotherapy. The more pronounced 1 O 2 generation of the 3‐hydroxypyridine complexes in acidic media and their specific accumulation within the acidic lysosomes of cancer cells highlight the potential of bioorthogonal prodrug activation for effective cancer‐targeted therapy.
- 21 October 2025
- Published by Wiley in Angewandte Chemie
- Vol. 137 (50)
Open AccessControlled Dual Activation of Rhenium(I) Photosensitizers and Profluorophores/Prodrugs via a Dissociative Bioorthogonal Tetrazine–Isonitrile Reaction
Strategies for prodrug activation have been developed to enhance treatment efficacy, with bioorthogonal dissociation reactions emerging as a promising approach due to their remarkable specificity. In this work, we designed three rhenium(I) polypyridine complexes featuring a tetrazylmethyl (TzMe) group capable of bioorthogonal activation by 3‐isocyanopropyl (ICPr) or 3‐isocyanopropyl‐1‐carbamoyl (ICPrc) derivatives. This design serves as a dual‐release platform, which liberates rhenium(I) 3‐hydroxypyridine complexes and functional payloads from rhenium(I) TzMe complexes and ICPr/ICPrc‐caged compounds, respectively. Upon incubation with an ICPrc derivative, the TzMe complexes exhibited strong emission in acidic buffers, attributed to the predominant existence of the resulting rhenium(I) 3‐hydroxypyridine complexes in their protonated form. Confocal imaging of live cells incubated with a TzMe complex and ICPr‐caged fluorescein unveiled intense intracellular emission in distinct channels. Importantly, the therapeutic potential of this approach was underscored by the treatment of cells with a TzMe complex and ICPrc‐caged doxorubicin. The anticancer effect was amplified through the synergy between singlet oxygen ( 1 O 2 ) photosensitization and prodrug activation, effectively combining photodynamic therapy with chemotherapy. The more pronounced 1 O 2 generation of the 3‐hydroxypyridine complexes in acidic media and their specific accumulation within the acidic lysosomes of cancer cells highlight the potential of bioorthogonal prodrug activation for effective cancer‐targeted therapy.
- Open Access
- 21 October 2025
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 64 (50) , e202516957
Controlled Dual Activation of Rhenium(I) Photosensitizers and Profluorophores/Prodrugs via a Dissociative Bioorthogonal Tetrazine–Isonitrile Reaction
Strategies for prodrug activation have been developed to enhance treatment efficacy, with bioorthogonal dissociation reactions emerging as a promising approach due to their remarkable specificity. In this work, we designed three rhenium(I) polypyridine complexes featuring a tetrazylmethyl (TzMe) group capable of bioorthogonal activation by 3‐isocyanopropyl (ICPr) or 3‐isocyanopropyl‐1‐carbamoyl (ICPrc) derivatives. This design serves as a dual‐release platform, which liberates rhenium(I) 3‐hydroxypyridine complexes and functional payloads from rhenium(I) TzMe complexes and ICPr/ICPrc‐caged compounds, respectively. Upon incubation with an ICPrc derivative, the TzMe complexes exhibited strong emission in acidic buffers, attributed to the predominant existence of the resulting rhenium(I) 3‐hydroxypyridine complexes in their protonated form. Confocal imaging of live cells incubated with a TzMe complex and ICPr‐caged fluorescein unveiled intense intracellular emission in distinct channels. Importantly, the therapeutic potential of this approach was underscored by the treatment of cells with a TzMe complex and ICPrc‐caged doxorubicin. The anticancer effect was amplified through the synergy between singlet oxygen ( 1 O 2 ) photosensitization and prodrug activation, effectively combining photodynamic therapy with chemotherapy. The more pronounced 1 O 2 generation of the 3‐hydroxypyridine complexes in acidic media and their specific accumulation within the acidic lysosomes of cancer cells highlight the potential of bioorthogonal prodrug activation for effective cancer‐targeted therapy.
- 21 October 2025
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 64 (50) , e202516957
Open AccessControlled Dual Activation of Rhenium(I) Photosensitizers and Profluorophores/Prodrugs via a Dissociative Bioorthogonal Tetrazine–Isonitrile Reaction
Strategies for prodrug activation have been developed to enhance treatment efficacy, with bioorthogonal dissociation reactions emerging as a promising approach due to their remarkable specificity. In this work, we designed three rhenium(I) polypyridine complexes featuring a tetrazylmethyl (TzMe) group capable of bioorthogonal activation by 3‐isocyanopropyl (ICPr) or 3‐isocyanopropyl‐1‐carbamoyl (ICPrc) derivatives. This design serves as a dual‐release platform, which liberates rhenium(I) 3‐hydroxypyridine complexes and functional payloads from rhenium(I) TzMe complexes and ICPr/ICPrc‐caged compounds, respectively. Upon incubation with an ICPrc derivative, the TzMe complexes exhibited strong emission in acidic buffers, attributed to the predominant existence of the resulting rhenium(I) 3‐hydroxypyridine complexes in their protonated form. Confocal imaging of live cells incubated with a TzMe complex and ICPr‐caged fluorescein unveiled intense intracellular emission in distinct channels. Importantly, the therapeutic potential of this approach was underscored by the treatment of cells with a TzMe complex and ICPrc‐caged doxorubicin. The anticancer effect was amplified through the synergy between singlet oxygen ( 1 O 2 ) photosensitization and prodrug activation, effectively combining photodynamic therapy with chemotherapy. The more pronounced 1 O 2 generation of the 3‐hydroxypyridine complexes in acidic media and their specific accumulation within the acidic lysosomes of cancer cells highlight the potential of bioorthogonal prodrug activation for effective cancer‐targeted therapy.